Lessons from Structural Biology for Understanding Drug Resistance in Gastrointestinal Stromal Tumors (GIST)

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Gastrointestinal stromal tumors (GISTs) are driven by mutations in KIT or PDGFRA receptor tyrosine kinases.
• Targeted therapies, such as tyrosine kinase inhibitors (TKIs), have improved GIST patient outcomes.
• Acquired drug resistance remains a significant challenge, limiting the long-term effectiveness of these treatments.

Purpose of the Study:

• To review the structural insights into the molecular mechanisms of acquired drug resistance in GISTs.
• To elucidate how secondary and tertiary mutations in KIT and PDGFRA kinases contribute to TKI resistance.
• To highlight the interplay between kinase activation, TKI binding, and resistance mutations.

Main Methods:

• This study is a perspective piece, synthesizing existing research and structural data.
• Analysis of published literature on GIST mutations, kinase structure, and drug resistance mechanisms.
• Focus on structural biology insights into kinase domain alterations.

Main Results:

• Secondary and tertiary mutations in distinct kinase domain regions alter kinase conformation and TKI binding.
• Specific mutations disrupt critical residues involved in drug interaction or kinase activity regulation.
• These alterations lead to reduced TKI efficacy and treatment failure.

Conclusions:

• A deep understanding of the structural basis of GIST drug resistance is essential.
• Identifying resistance mutation patterns can guide the development of next-generation TKIs.
• Future therapeutic strategies must address the molecular mechanisms underlying acquired resistance to improve long-term GIST management.